Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy ...

Abstract: Microcontroller-driven battery management systems (BMS) are crucial for various applications, including electric vehicles, portable electronics, and renewable energy storage. These systems ...

Change base from pcbcupid: master +381 −0 Conversation 6 Commits 7 Checks 23 Files changed 3 Open feat (board) : Added board Glyph S3 (esp32s3 based board with on board BMS) #12666 Show file tree Hide ...

BMS' first-quarter revenues climbed 3% to $11.5 billion, with $6.2 billion of the haul coming from its newer growth product portfolio. (Angus Liu/Fierce Pharma) Bristol Myers Squibb’s growth portfolio ...

Abstract: This paper presents about the Smart Battery Management System (BMS) using Arduino controller and NodeMCU. The battery management system is designed to monitor the parameter of battery ...

BMS CEO Christopher Boerner said the company is confident relying on pipeline assets to cover revenues to be lost with patent expiries for Opdivo and Eiquis. Credit: PixelBliss/Shutterstock.com ...

Lithium-ion batteries are a key enabling technology for electric vehicles (EVs) 1 due to their high energy density, efficiency, and rechargeability. However, their performance and safety are not ...

Nearly 4,500 Tesla Model 3 and Model Y owners in South Korea have complained about battery malfunctions that prevent charging. The problem, which primarily affects 2021 models, has drawn the scrutiny ...

Bristol Myers Squibb is securing an opportunity to compete in the next generation of cell therapies through the $1.5 billion acquisition of Orbital Therapeutics, a startup with a lead program nearing ...

The PD.Charger-GSM v2.5 is an industrial-grade solar and LiFePo4 charger/controller with MPPT support, designed for 2–4 cell Li-Ion/LiFePo4 batteries. With various connectivity options and a ...

Sigvotatug vedotin (SV), an investigational integrin beta-6 (IB6)–directed antibody‒drug conjugate (ADC), and pembrolizumab combination therapy: Initial results from an ongoing phase 1 study ...

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R&D), ...